Alexandria Hammond
Stock Analyst at Wolfe Research
(1.82)
# 3,510
Out of 4,579 analysts
47
Total ratings
50%
Success rate
0.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alexandria Hammond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintained: Buy | $1,325 → $1,350 | $1,197.53 | +12.73% | 6 | May 21, 2026 | |
| REGN Regeneron Pharmaceuticals | Reiterated: Buy | $1,150 → $860 | $667.17 | +28.90% | 2 | May 18, 2026 | |
| PFE Pfizer | Reiterated: Sell | $25 → $26 | $24.67 | +5.39% | 5 | May 13, 2026 | |
| MRK Merck & Co. | Upgraded: Buy | $135 | $130.76 | +3.24% | 3 | Jan 8, 2026 | |
| ABBV AbbVie | Downgraded: Hold | n/a | $256.91 | - | 2 | Jan 8, 2026 | |
| MRNA Moderna | Reiterated: Sell | $20 → $17 | $55.63 | -69.44% | 6 | Nov 20, 2025 | |
| JNJ Johnson & Johnson | Maintained: Buy | $200 → $225 | $265.95 | -15.40% | 7 | Oct 15, 2025 | |
| BMRN BioMarin Pharmaceutical | Reiterated: Buy | $95 | $60.27 | n/a | 3 | Jul 15, 2025 | |
| GILD Gilead Sciences | Initiated Coverage: Buy | $110 → $109 | $130.52 | n/a | 3 | Dec 10, 2024 | |
| AMGN Amgen | Initiated Coverage: Hold | n/a | $376.26 | n/a | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $200.14 | n/a | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $62.56 | n/a | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $150 | $551.25 | n/a | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $550 | $479.00 | n/a | 2 | Aug 2, 2024 |
Eli Lilly and Company
May 21, 2026
Maintained: Buy
Price Target: $1,325 → $1,350
Current: $1,197.53
Upside: +12.73%
Regeneron Pharmaceuticals
May 18, 2026
Reiterated: Buy
Price Target: $1,150 → $860
Current: $667.17
Upside: +28.90%
Pfizer
May 13, 2026
Reiterated: Sell
Price Target: $25 → $26
Current: $24.67
Upside: +5.39%
Merck & Co.
Jan 8, 2026
Upgraded: Buy
Price Target: $135
Current: $130.76
Upside: +3.24%
AbbVie
Jan 8, 2026
Downgraded: Hold
Price Target: n/a
Current: $256.91
Upside: -
Moderna
Nov 20, 2025
Reiterated: Sell
Price Target: $20 → $17
Current: $55.63
Upside: -69.44%
Johnson & Johnson
Oct 15, 2025
Maintained: Buy
Price Target: $200 → $225
Current: $265.95
Upside: -15.40%
BioMarin Pharmaceutical
Jul 15, 2025
Reiterated: Buy
Price Target: $95
Current: $60.27
Upside: n/a
Gilead Sciences
Dec 10, 2024
Initiated Coverage: Buy
Price Target: $110 → $109
Current: $130.52
Upside: n/a
Amgen
Nov 14, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $376.26
Upside: n/a
Nov 14, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $200.14
Upside: n/a
Nov 14, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $62.56
Upside: n/a
Aug 7, 2024
Reiterated: Sell
Price Target: $150
Current: $551.25
Upside: n/a
Aug 2, 2024
Reiterated: Buy
Price Target: $550
Current: $479.00
Upside: n/a